RCUS Form 144: 100,583 shares via J.P. Morgan on 10/06/2025

Rhea-AI Filing Summary

Arcus Biosciences, Inc. filed a Form 144 reporting a proposed sale of 100,583 shares of common stock through J.P. Morgan Securities LLC on 10/06/2025. The filing shows the shares were acquired and paid for on 10/06/2025 via a stock option exercise with payment in cash. The aggregate market value listed for the shares to be sold is 1,342,783 and the total shares outstanding are 106,430,976, which implies the block represents roughly 0.095% of outstanding shares. No other sales in the past three months were reported and no seller name is disclosed in the public sections of the form.

Positive

• Sale follows same‑day stock option exercise, indicating proceeds stem from exercised options rather than secondary transfer
• Block size is small at ~0.095% of outstanding shares, limiting standalone market impact
• Brokered sale through J.P. Morgan Securities LLC, a major dealer, which can facilitate orderly execution

Negative

• Insider sale planned, which some investors may view negatively absent an explanatory statement
• No seller identity disclosed in the public sections provided, reducing transparency for investors

Insights

Insider Transactions Analyst

Insider exercised options and is placing a modest block for sale the same day.

The filing shows 100,583 shares were acquired by stock option exercise and the holder intends to sell those shares via J.P. Morgan Securities LLC on 10/06/2025. The transaction was paid in cash on the acquisition date.

Because the block is about 0.095% of the 106,430,976 shares outstanding, the direct market impact is likely limited in size. Monitor actual trade execution timing on 10/06/2025 and any subsequent Form 4 filings that would identify the seller.

Market Impact Specialist

Reported sale size is small relative to total float and unlikely to materially move the stock alone.

The reported aggregate market value for the block is 1,342,783, and the sale is scheduled for 10/06/2025 on NYSE. Execution by a major broker could smooth any price impact.

Key near-term items to watch are trade completion on 10/06/2025 and whether additional insider selling is reported; absent further filings, this single planned sale appears limited in scale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017	100583	1342783	106430976	10/06/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/06/2025	Stock Option Exercise	Issuer			100583	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Arcus Biosciences (RCUS) report on Form 144?

The filing reports a proposed sale of 100,583 shares of common stock to be sold via J.P. Morgan Securities LLC on 10/06/2025.

How were the shares acquired for the RCUS Form 144 sale?

The shares were acquired on 10/06/2025 through a stock option exercise, with payment made in cash.

What is the aggregate market value and percent of outstanding shares?

The aggregate market value reported is 1,342,783, representing roughly 0.095% of the 106,430,976 shares outstanding.

Is there any selling history in the past three months for this account?

The filing states "Nothing to Report" for securities sold during the past three months by the account.

Which exchange will the sale occur on?

The proposed sale is listed for execution on the NYSE.